Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute
for Health Innovation (IHI) today announced a strategic
collaboration to collect and analyze genetic and electronic health
data that can enhance the understanding of nonalcoholic
steatohepatitis (NASH) and potentially inform development of
treatment options for the disease.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190711005257/en/
Under the terms of the collaboration and license agreement,
Gilead will provide funding to Renown IHI to sequence and analyze
the DNA of 15,000 individuals living with NASH or nonalcoholic
fatty liver disease (NAFLD) as well as a control cohort of 40,000
individuals in Nevada.
“Combining the sequencing of protein coding DNA, with extensive
electronic health record data will enable a deep analysis of the
roles of genetics and environment in NASH incidence and
progression,” said John McHutchison, AO, MD, Chief Scientific
Officer and Head of Research and Development, Gilead Sciences. “The
analysis of these large datasets in collaboration with Renown IHI
could help identify genetic variants that impact the risk of
developing NASH and thereby advance the discovery and development
of new treatments for this disease.”
Renown Health is Nevada’s most comprehensive and integrated
healthcare network and maintains electronic health records for 1.02
million registered patients. In 2016, Renown Health and the Desert
Research Institute established the Healthy Nevada Project (HNP),
the nation’s first community-based population health study. In 2017
HNP began a partnership with Helix to leverage its population
health services, Exome+™ sequencing, and consumer engagement tools.
The HNP is now an ongoing collaboration between Renown IHI, the
Desert Research Institute, a global leader in environmental data
and applied research, and Helix, a personal genomics company. HNP
combines genetic, environmental, social and clinical data to
address individual and community health needs with the goal of
improving health across the state and the nation. The HNP currently
has 40,000 participants.
“Combining genetic sequencing with large sets of data can play a
critical role in understanding and identifying serious health
risks, including diseases like NASH. We are excited to collaborate
with Gilead to better understand the condition and its
complexities,” said Anthony Slonim, MD., DrPH. “Any genetic
variants identified in participants through the collaboration may
be shared with the participants for patient care purposes.”
About NASH
Nonalcoholic steatohepatitis (NASH) is a chronic form of liver
disease characterized by excess fat in the liver, inflammation, and
liver cell damage. Inflammation and liver cell damage can cause
scarring of the liver, or fibrosis, and ultimately lead to
cirrhosis or liver cancer. NASH is more common in people with
certain conditions, including obesity and type 2 diabetes. There
are currently limited approved treatments for patients living with
NASH.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
About Renown Health
Renown Health is a locally governed and locally owned,
not-for-profit integrated healthcare network serving Nevada, Lake
Tahoe and northeast California. Renown is one of the region’s
largest private employers with a workforce of more than 7,000. It
comprises three acute care hospitals, a rehabilitation hospital,
the area’s most comprehensive medical group and urgent care
network, and the region’s largest and only locally owned
not-for-profit insurance company, Hometown Health. Renown Health’s
commitment has extended beyond traditional health care to include
community health and well-being. Renown Health works to improve
health care through science, research and genetics; forge community
partnerships that improve lives and develop innovative models that
are improving health care in Nevada. For more information, visit
renown.org and follow Dr. Tony Slonim on Twitter
@RenownCEOTonyMD.
About Helix
Helix’s mission is to empower every person to improve their life
through DNA. Helix is accelerating the integration of genomic data
into clinical care and broadening the impact of large-scale
population health programs by providing comprehensive expertise in
DNA sequencing, bioinformatics, and individual engagement. Powered
by their proprietary Exome+™ assay—a panel-grade exome enhanced by
more than 300,000 informative non-coding regions—Helix offers
health systems a scalable solution which enables the discovery of
medically relevant, potentially life-saving, genetic information.
Additionally, Helix offers a suite of DNA-powered products for
continued individual engagement and discovery.
Helix is headquartered in the San Francisco Bay Area and has one
of the world’s largest CLIA-certified, CAP-accredited Next
Generation Sequencing labs, located in San Diego, California. Learn
more at www.helix.com.
Helix, the Helix logo, and Exome+ are trademarks of Helix Opco,
LLC
Gilead Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that the parties may not realize the potential
benefits of this collaboration, and Gilead may fail to discover,
develop and commercialize any product candidates for the treatment
of NASH. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements.
These risks, uncertainties and other factors could cause actual
results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. These and other risks are
described in detail in Gilead’s Quarterly Report on Form 10-Q for
the quarter ended March 31, 2019, as filed with the U.S. Securities
and Exchange Commission. All forward-looking statements are based
on information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005257/en/
Gilead Contacts: Sung Lee, Investors (650) 524-7792
Arran Attridge, Media (650) 425-8975
Renown Contact: Stacey Sunday (775) 982-4302
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024